|
 MITL, Mitel Networks Corp.
** On its fourth quarter fiscal 2012, MITL posted revenue from continuing operations of $157.6 million, a 4% increase year over year, and net income from continuing operations of $49.8 million (included the relief of a valuation allowance of approximately $35.0 million primarily relating to MITL's deferred tax assets in Canada), or $0.89 per share, diluted, compared to a net income of $3.9 million, or $0.07 per share, diluted, in the same period the prior year. MITL is a global provider of business communications and collaboration software and services. More about MITL at www.mitel.com. **********  IDIX, Idenix Pharmaceuticals Inc.
** IDIX reported positive clinical data for Hepatitis C virus drug-candidates IDX184 and IDX719. IDX184 is an unpartnered, novel, liver-targeted nucleotide prodrug of 2'-methyl guanosine, which includes IDIX's proprietary liver-targeting technology. This technology enables the delivery of nucleoside monophosphate to the liver, leading to the formation of high levels of nucleoside triphosphate, potentially maximizing drug efficacy and limiting systemic side effects with low, once-daily dosing. IDX719 is an NS5A inhibitor with low picomolar, pan-genotypic antiviral activity in vitro. Hepatitis C virus is a common blood-borne pathogen infecting three to four million people worldwide annually. The World Health Organization (WHO) estimates that more than 170 million people worldwide are chronicallay infected with HCV, representing a nearly 5-fold greater prevalence than human immunodeficiency virus. IDIX is a biopharmaceutical Company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with HCV. More about IDIX at www.idenix.com. *************  GEVO, Gevo, Inc.
** GEVO reported that it has signed a collaborative agreement with the intent to site a cellulosic biomass isobutanol facility in Southeast Asia. GEVO?s President and Chief Operating Officer, Chris Ryan, signed the collaborative agreement with representatives from the Malaysian government?s East Coast Economic Region Development Council (ECERDC), Malaysian Biotechnology Corp (BiotechCorp) and the State Government of Terengganu. After a year of ongoing development work in Malaysia, GEVO is strategically partnering along the supply chain to provide biobased isobutanol at a cost competitive price. GEVO is in the final stages of evaluating additional partners to complete the biomass to isobutanol value chain. The collaboration offers a diversified feedstock, organized approach and the opportunity to develop an economically advantaged business plan to meet this expanding market. The current plan under consideration is to construct a fermentation facility to produce bio isobutanol made from cellulosic biomass. The proposed site is in the State of Terengganu at the world-class Biorefinery Complex in Kertih. GEVO is converting existing ethanol plants into biorefineries to make renewable building block products for the chemical and fuel industries. GEVO plans to convert renewable raw materials into isobutanol and renewable hydrocarbons that can be directly integrated on a ?drop in? basis into existing chemical and fuel products to deliver environmental and economic benefits. More about GEVO at www.gevo.com. ******************************** THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE) advertises for a particular client, Crown Equity Holdings Inc. (CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE), if paid in stock, can and may sell those securities during the advertising period.
Related Articles -
Mitel Networks, Nasdaq:MITL, GEVO, Nasdaq:GEVO, IDIX, Idenix Pharmaceuticals, Nasdaq:IDIX,
| 
